Comparative Advertising: Lessons to Be Learned from a Recent Case in Point

Abstract

Within the past year, a number of comparative advertising campaigns have been cited by the Food and Drug Administration as being false and misleading. Analysis of a portion of one of these campaigns sheds light on what is and is not permissible in comparative advertising, and reveals six painful lessons for all who are involved in the development or review of pharmaceutical promotional material.